Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

, Benzinga -  3:38 PM ET 4/4/2025 Investing Ideas

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

Arvinas, Inc ( ARVN ). unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102.

Results from the randomized, double-blind, placebo-controlled single ascending dose (SAD) cohort of the Phase 1 healthy volunteer trial and initial results from the multiple ascending dose (MAD) cohort were shared in a presentation at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.

The Phase 1 trial included SAD cohorts from 10 mg to 200 mg and MAD cohorts of 10 mg to 80 mg in healthy volunteers.

In the trial ARV-102, the company’s investigational PROteolysis TArgeting Chimera (PROTAC) leucine-rich repeat kinase 2 (LRRK2) degrader, demonstrated substantial reduction of LRRK2, a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy (PSP), in cerebral spinal fluid (CSF).

Also Read: Arvinas ( ARVN ), Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

The trial also showed an encouraging safety/tolerability profile and favorable pharmacodynamic outcomes.

A single oral dose of at least 60 mg ARV-102 induced more than 50% reduction of LRRK2 protein in cerebrospinal fluid and over 90% reduction in peripheral blood mononuclear cells.

While LRRK2 is primarily known for its role in Parkinson’s, Arvinas ( ARVN ) noted that emerging evidence suggests it also plays a role in tauopathies, including progressive supranuclear palsy (PSP).

Arvinas ( ARVN ) added that early data suggest the drug was well tolerated. Data from 47 volunteers across all SAD dose levels showed the most common treatment-related issues were headaches (17.1%) and fatigue (8.6%), although fatigue was more common among placebo recipients (25%).

In the fourth quarter of 2024, Arvinas ( ARVN ) initiated dosing in the SAD cohort of the Phase 1 clinical trial with ARV-102 in patients with Parkinson’s disease.

The company expects to complete enrollment and present initial data from the ongoing SAD cohort of the Phase 1 trial in patients with Parkinson’s disease and initiate the MAD cohort of the Phase 1 clinical trial in patients with Parkinson’s disease in 2025.

Price Action: ARVN stock is down 4.93% at $6.56 at the last check on Friday.

Read Next:

  • Rogers Scores $5 Billion Blackstone Deal To Cut Debt, Unlock Wireless Infrastructure Value

Photo by Berit Kessler via Shutterstock

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.